Clinical Trial Update: Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on bevacizumab for metastatic triple negative breast cancer; evaluates efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Assiut University | Conditions: Metastatic Triple Negative Breast Cancer, Safety Issues | Phase 2 | Status: COMPLETED